Treatment modalities and oncological outcomes in Mexican patients with localized gastric cancer

Autor:	Luis Guillermo Anaya Sánchez, Vanessa Rosas Camargo, Haydee Cristina Verduzco-Aguirre, Mónica Isabel Meneses Medina, Ana Karen Valenzuela, Fidel David Huitzil-Melendez, Edwin Ulises Cortez Dominguez
Rok vydání:	2020
Předmět:	Oncology Cancer Research medicine.medical_specialty business.industry Cancer Limiting medicine.disease Early Gastric Cancer Treatment modality Internal medicine medicine Treatment strategy business
Zdroj:	Journal of Clinical Oncology. 38:319-319
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2020.38.4_suppl.319
Popis:	319 Background: gastric cancer is common in Mexico. Evaluation of treatment strategies is greatly important in early gastric cancer. National institutions rarely report their outcomes, limiting feedback and policy improvements. Methods: single-center retrospective review of patients with histologically confirmed localized gastric cancer diagnosed from Jan 2005 to Dec 2017. Overall survival (OS) and recurrence-free survival (RFS) were estimated by Kaplan-Meier curves and compared with log-rank rest. A p value < 0.05 was significant. Results: we included 78 cases, median age 63 years, 52.6% men. Surgery was the initial treatment in 46 patients (59%) and 87% achieved R0 resection. Adjuvant treatment was administered to 63% of patients. 29 patients (37.2%) started perioperative chemotherapy with 86.2% of them being resected, and 75.9% having R0 resection. 13 patients (44.8%) also received postoperative chemotherapy. Better performance status (p=0.036) and lower albumin levels (p=0.039) were found in patients with initial surgery vs those with perioperative chemotherapy. At the time of surgery, most patients had stage III disease in both groups but 5 patients had M1 disease despite negative initial laparoscopy in the chemotherapy group and 5 patients did not require aduvant tx given early stage in the surgery first group. Median OS and RFS are reported in table. Conclusions: Most patients in our center undergo initial surgery. We report a differential survival according to initial treatment. More advanced disease in chemotherapy first group may explain differences. Given non-random assignment, we could not show survival benefit of chemotherapy treated patients. [Table: see text]
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::a55f9a0f13d4a7af3db1753a3733a934 https://doi.org/10.1200/jco.2020.38.4_suppl.319 Zobrazit plný text záznamu